Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-29. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
C. brunneus produce song by moving stridulatory pegs against their elytra. The normal calling song consists of 5-12 notes that range between 0.25 and 0.50 seconds in length. Notes are followed by a 3-second period of rest. Males will repeat the song at intervals. Males produce a rival song when they come into contact with other males. C. brunneus males produce sounds during the pauses of the other males' song. Notes in the rival song are produced three to four times faster than notes produced in the normal song. In the normal song notes are produced every 1.5–2 seconds but in the rival song notes are produced every 0.35–0.57 seconds. Courtship songs are produced after the male produces some notes from his normal song and fails to copulate. Courtship songs in C. brunneus consist of softer notes similar to the normal song produced at higher frequencies. After producing the song for a duration the male will attempt to copulate with the female. If he is unsuccessful he will produce several short, loud notes before producing the courtship song again. A receptive female will respond to the male's song leading to the alteration of song between her and the male. This is called the attraction song. Male C. brunneus not only produce several different types of calls, they also show variation in characteristics of the same song. Stabilizing selection has acted on male C. brunneus song. Males with intermediate song characteristics are most successful while males with extreme characteristics are the least successful in attracting a mate. Song production is sensitive to the environment.
=== 2006–2016: Big Love and final roles === In 2006, Chase secured the role of Rhonda Volmer in Big Love, a critically acclaimed drama series on HBO which centered on a polygamist family in Utah led by patriarch Bill Henrickson (Bill Paxton). Chase's character, Rhonda, was introduced as the teenage child bride of the compound's ruthless prophet, Roman Grant (Harry Dean Stanton). Chase remained a recurring and main presence on the series until its conclusion in 2011, earning praise for her chilling depiction of a young woman corrupted by religious extremism. Also in 2006, Chase voiced Lilo for the final time in Leroy & Stitch, the conclusion to the Lilo & Stitch television series. In 2008, she took on the voice role of Betsy in the PBS Kids educational animated series Betsy's Kindergarten Adventures. In 2009, Chase reprised her Donnie Darko role as Samantha in the sequel S. Darko. Set seven years after the events of the original film, the narrative follows an 18-year-old Samantha on a cross-country road trip to Los Angeles, where she becomes plagued by bizarre visions and time anomalies. Unlike its predecessor, S. Darko received overwhelmingly negative reviews from critics. Having been made without the approval of (nor input from) the original film's creator, Richard Kelly, the sequel shares minimal continuity with its predecessor. During the 2010s, Chase appeared primarily in independent thriller and horror films. She played a supporting role in the drama Yellow (2012) and starred in the independent thriller Killer Crush (2015).
== Contaminant == A contaminant is a substance present in nature at a level higher than fixed levels or that would not otherwise be there. This may be due to human activity and bioactivity. The term contaminant is often used interchangeably with pollutant, which is a substance that detrimentally impacts the surrounding environment. While a contaminant is sometimes a substance in the environment as a result of human activity, but without harmful effects, it is sometimes the case that toxic or harmful effects from contamination only become apparent at a later date. The "medium" such as soil or organism such as fish affected by the pollutant or contaminant is called a receptor, whilst a sink is a chemical medium or species that retains and interacts with the pollutant such as carbon sink and its effects by microbes.
Sources: en.wikipedia.org
== Diagnosis == One of the most important factors used to determine the clinical suspicion of malignancy of an adnexal mass is the sonographic (ultrasound) appearance of the mass. Indications that the mass is at a higher risk of being malignant include the presence of loculations, nodules, papillary structures, septations, or a size greater than 10 cm.
Over the first three-quarters of the 19th century, many experimenters worked with various combinations of platinum or iridium wires, carbon rods, and evacuated or semi-evacuated enclosures. Many of these devices were demonstrated and some were patented. In 1835, James Bowman Lindsay demonstrated a constant electric light at a public meeting in Dundee, Scotland. He stated that he could "read a book at a distance of one and a half feet". However he did not develop the electric light any further. In 1838, Belgian lithographer Marcellin Jobard invented an incandescent light bulb with a vacuum atmosphere using a carbon filament. In 1840, British scientist Warren De la Rue enclosed a coiled platinum filament in a vacuum tube and passed an electric current through it. The design was based on the concept that the high melting point of platinum would allow it to operate at high temperatures and that the evacuated chamber would contain fewer gas molecules to react with the platinum, improving its longevity. Although a workable design, the cost of the platinum made it impractical for commercial use. In 1841, Frederick de Moleyns of England was granted the first patent for an incandescent lamp, with a design using platinum wires contained within a vacuum bulb. He also used carbon. In 1845, American John W. Starr patented an incandescent light bulb using carbon filaments. His invention was never produced commercially. In 1851, Jean Eugène Robert-Houdin publicly demonstrated incandescent light bulbs on his estate in Blois, France.
Grand Master Filema Duarte then stripped former Grand Master Urquía Carreño of all his Masonic rights, and referred him to appear in front of the Supreme Court of Masonic Justice, so that they could review the case. On September 10, 2024, Urquía Carreño was then arrested and taken into custody by the National Revolutionary Police at Zanja y Dragones Police Station, the same police station which had launched the theft investigation on January 12. His official charge was the embezzlement of $MN754,410.54 and US$2,700. Urquía Carreño and Airam Cervera were given a travel limit by the Cuban government, prevented from leaving the island with any potential stolen cash. In 2025, Urquía Carreño gave an interview on a YouTube channel associated with the Cuban government in which he denied all wrongdoing, and reiterated his belief that Viñas Alonso was the leader of an anti-government conspiracy alongside Gerardo Cepero and Ángel Santiesteban to remove him from office. He insisted that everything had been orchestrated by this group, beginning with the theft and ending with Urquía Carreño's eventual resignation.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.